Search

Your search keyword '"Schellekens, Huub"' showing total 667 results
Start Over Author "Schellekens, Huub"
667 results on '"Schellekens, Huub"'

19. Biosimilar epoetins

Author

Schellekens, Huub, Pharham, Michael J., editor, Bruinvels, J., editor, Elliott, Steven G., editor, Foote, Mary Ann, editor, and Molineux, Graham, editor

Published
2009
Full Text
View/download PDF

20. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases

Author

Kay, Jonathan, Schoels, Monika M, Dörner, Thomas, Emery, Paul, Kvien, Tore K, Smolen, Josef S, Breedveld, Ferdinand C, Bijlsma, Johannes Wj, Braun, Jürgen, Bykerk, Vivian P, Danese, Silvio, De wit, Maarten Pt, Goncalves, João, Huizinga, Tom Wj, Isaacs, John D, Kavanaugh, Arthur F, Kurki, Pekka, Luger, Thomas A, Müller-ladner, Ulf, Pavelka, Karel, Schellekens, Huub, Strangfeld, Anja, Takeuchi, Tsutomu, Voshaar, Marieke, and Weisman, Michael H

Published
2018
Full Text
View/download PDF

23. Pathways in the Drug Development for Alzheimer’s Disease (1906-2016): A Bibliometric Study

Author

Schilder, Isabel PA, Veening-Griffioen, Désirée H, Ferreira, Guilherme S, Meer, Peter JK Van, Wied, Christine C Gispen-de, Schellekens, Huub, Boon, Wouter PC, Moors, Ellen HM, Afd Pharmaceutics, Innovation and Sustainability, Innovation Studies, and Pharmaceutics

Subjects
Thematic evolution, business.industry, Drug development, Disease, Alzheimer's disease, Library and Information Sciences, Bioinformatics, Co-word analysis, Computer Science Applications, Citation analysis, Medicine, Main path analysis, business, Information Systems
Abstract

Investments in drug development for Alzheimer's disease (AD) have not led to the availability of a treatment to cure or halt the progression of the disease. This study aimed to provide insights into the current lack of an effective therapy against AD by exploring the evolution of research paths in the scientific domains corresponding to fundamental, preclinical and clinical research from the identification of the disease in 1906 up to 2016. More specifically, the influence of the amyloid cascade hypothesis and use of animal models in the evolution of drug development for AD were explored. We used bibliometric analysis for the identification of research paths taken over time, including main path analysis, direct citation analysis and co-word analysis. The results show that the amyloid cascade hypothesis has played an important role in the evolution of research paths in the drug development process of AD. The preclinical domain and to a lesser extent the clinical domain, were found to be increasingly involved in the study of interventions modulating amyloid-beta related neurotoxicity over time in line with the fundamental domain predominantly focussing on amyloid-beta as the primary cause of AD. The results open up a discussion about lock-in, i.e. that decreasing options in the fundamental domain results in less room for manoeuvre in the preclinical and clinical domain.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results